Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.India-based pharmaceutical company Biological E.
has signed an agreement with Johnson & Johnson (J&J) unit Janssen Pharmaceutica to manufacture J&J’s Covid-19 vaccine candidate, Ad26.COV2.S.
Under the terms of the deal, Biological E. will boost production capacities for drug substance and drug product of the vaccine candidate, which is currently in Phase I/IIa clinical trials.
BE novel vaccine initiative head and BioE Holdings director Narender Dev Mantena said: “We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its Covid-19 vaccine.” Biological E.